HC Wainwright Issues Optimistic Outlook for CRSP Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP) – Analysts at HC Wainwright raised their Q2 2025 earnings per share estimates for CRISPR Therapeutics in a report released on Wednesday, May 7th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings per share of ($0.93) for the quarter, up from their previous estimate of ($1.01). HC Wainwright has a “Buy” rating and a $65.00 price objective on the stock. The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.16) per share. HC Wainwright also issued estimates for CRISPR Therapeutics’ Q3 2025 earnings at ($1.07) EPS and FY2025 earnings at ($4.57) EPS.

CRSP has been the topic of several other reports. StockNews.com raised CRISPR Therapeutics to a “sell” rating in a research report on Friday, March 21st. The Goldman Sachs Group dropped their target price on CRISPR Therapeutics from $53.00 to $47.00 and set a “neutral” rating on the stock in a research report on Thursday, May 8th. Stifel Nicolaus dropped their target price on CRISPR Therapeutics from $53.00 to $49.00 and set a “hold” rating on the stock in a research report on Thursday, February 13th. Morgan Stanley lifted their price objective on CRISPR Therapeutics from $30.00 to $32.00 and gave the company an “underweight” rating in a research report on Friday, February 14th. Finally, Evercore ISI raised shares of CRISPR Therapeutics from an “in-line” rating to an “outperform” rating and increased their target price for the stock from $60.00 to $99.00 in a report on Friday, February 14th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and ten have given a buy rating to the company. According to MarketBeat.com, CRISPR Therapeutics presently has an average rating of “Hold” and a consensus price target of $71.75.

CRISPR Therapeutics Stock Performance

Shares of NASDAQ:CRSP opened at $37.22 on Monday. The stock has a market capitalization of $3.21 billion, a price-to-earnings ratio of -8.52 and a beta of 1.88. The stock’s 50-day simple moving average is $38.03 and its two-hundred day simple moving average is $42.64. CRISPR Therapeutics has a 52-week low of $30.04 and a 52-week high of $67.88.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. CRISPR Therapeutics’s revenue for the quarter was up 71.6% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.43) earnings per share.

Institutional Investors Weigh In On CRISPR Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of CRSP. ARK Investment Management LLC raised its position in shares of CRISPR Therapeutics by 19.7% during the fourth quarter. ARK Investment Management LLC now owns 8,973,064 shares of the company’s stock valued at $353,180,000 after buying an additional 1,474,439 shares during the last quarter. T. Rowe Price Investment Management Inc. raised its position in shares of CRISPR Therapeutics by 39.2% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,811,708 shares of the company’s stock valued at $150,029,000 after buying an additional 1,074,238 shares during the last quarter. Capital International Investors raised its position in shares of CRISPR Therapeutics by 10.3% during the fourth quarter. Capital International Investors now owns 8,743,523 shares of the company’s stock valued at $344,145,000 after buying an additional 816,789 shares during the last quarter. Baker BROS. Advisors LP increased its position in CRISPR Therapeutics by 55.1% in the fourth quarter. Baker BROS. Advisors LP now owns 1,308,011 shares of the company’s stock worth $51,483,000 after purchasing an additional 464,936 shares during the last quarter. Finally, Norges Bank bought a new stake in CRISPR Therapeutics in the fourth quarter worth $17,458,000. Institutional investors own 69.20% of the company’s stock.

Insider Buying and Selling at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 18,360 shares of CRISPR Therapeutics stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total transaction of $1,013,472.00. Following the sale, the chief executive officer now owns 171,613 shares in the company, valued at $9,473,037.60. This trade represents a 9.66% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, COO Julianne Bruno sold 1,198 shares of CRISPR Therapeutics stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total transaction of $50,819.16. Following the sale, the chief operating officer now owns 8,263 shares in the company, valued at approximately $350,516.46. The trade was a 12.66% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 32,381 shares of company stock valued at $1,608,243 over the last 90 days. 4.30% of the stock is currently owned by corporate insiders.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.